Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMercia Asset Regulatory News (MERC)

Share Price Information for Mercia Asset (MERC)

Share Price is delayed by 15 minutes
Get Live Data
28.75    0.00 (0.00%)
Bid:
28.50
Ask:
29.00
Spread: 0.50 (1.754%)
Market Cap: £121.51m
MERC Live PriceLast checked at - London Stock Exchange

Intraday Mercia Asset Share Chart

Trading Update

1 May 2008 07:01

Merchant Securities PLC01 May 2008 1 May 2008 Merchant Securities plc ("Merchant Securities" or the "Company") Trading update The Board of Merchant Securities, the financial services company specialising inprivate client and institutional stockbroking, corporate finance services andprivate equity, announces a trading update for the year ended 31March 2008. As stated at the time of the Company's interim announcement in December 2007,the Company continues to make progress in developing its core activities and instrengthening the infrastructure of its business. In this regard, the Companyhas achieved the following strategic developments in the second half of itsfinancial year: • Merchant Securities Group Limited, ("MSGL") its stockbroking subsidiary, became a member of the London Stock Exchange in February 2008; • A new, upgraded private client investment management system and a transfer of the settlement and clearing functions to Pershing in February 2008; • Its management team has been strengthened by the appointment of a new Chief Financial Officer and a new Compliance Officer; • In October 2007, it completed the acquisition of John East & Partners, a corporate finance adviser, nominated adviser and corporate broker, which made a positive contribution to the group, post acquisition, in the year ended 31 March 2008; • It has recruited a senior institutional research and sales team which is due to join MSGL within the next two months. As a result of these developments, a number of costs have been incurred. Inaddition, market conditions have deteriorated since the announcement of theCompany's interim results and a number of the larger private equity transactionsin progress at that time have not been completed as originally anticipated.Consequently, the Company expects that it will have incurred a loss aftertaxation in the region of £600,000, after taking account of non-recurring itemsof approximately £400,000, in the financial year ended 31 March 2008. The board continues to pursue its strategy of building a diversified financialservices group and some non-recurring reorganisation costs are an inevitableconsequence. The board remains confident that the successful implementation ofits strategy will see significant benefits accruing to the Company in the mediumterm. The Company expects to announce it results for the year ended 31 March 2008 inthe second half of July 2008. ENDS For further information please contact: Anthony Fabrizi Chief Executive 020 7375 9060 Merchant Securities Roland Cross Director 020 7726 6111 Broadgate Richard Day Director 020 7398 1600 Arden Partners plc This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
29th Jul 20192:24 pmRNSNotification of Major Holdings
26th Jul 20197:00 amRNSPublication of Annual Report
8th Jul 20197:00 amRNSPreliminary Results
5th Jul 201910:00 amRNSChange of Name
2nd Jul 20197:00 amRNSDirectorate Change
21st May 20197:00 amRNS£2.4million syndicated investment into Medherant
15th May 20197:00 amRNS£2.0million syndicated investment into Locate Bio
14th May 20197:06 amRNSConcepta PLC confirms first myLotus® pregnancies
2nd May 20197:00 amRNSNotice of Preliminary Results
11th Apr 20199:41 amRNSPDMR Dealing
10th Apr 20197:00 amRNSDirector/ PDMR Dealings
28th Mar 20197:00 amRNS£6.5m syndicated investment into Oxford Genetics
18th Mar 20194:23 pmRNSPDMR / Director Dealings
15th Mar 20191:19 pmRNSPDMR / Director Dealings
12th Mar 20197:06 amRNSPortfolio company Concepta secures partnership
28th Feb 20197:00 amRNSPortfolio company announces six licensing deals
20th Feb 20197:00 amRNSSoftware & the Internet Portfolio Update
5th Feb 20197:00 amRNSAppointment of NOMAD
3rd Dec 20187:00 amRNSHalf Year Results
31st Oct 20187:00 amRNSNotice of Results
29th Oct 20187:00 amRNSNew Direct Investment in W2 Global Data Solutions
18th Oct 20187:00 amRNSCapital Markets Day
16th Oct 20187:00 amRNSNew Emerging Star investment into Locate Bio
21st Sep 201810:47 amRNSResult of AGM
21st Sep 20187:00 amRNSAGM Statement
18th Sep 20187:00 amRNSAston EyeTech secures multi-million pound contract
13th Sep 20187:00 amRNSNotice of Capital Markets Day
29th Aug 20187:00 amRNSGrant of Options
16th Aug 20187:00 amRNSnDreams secures multi-million dollar contract
7th Aug 20187:00 amRNSOG wins significant multi-million pound contract
27th Jul 20189:30 amRNSPublication of Annual Report
17th Jul 20183:14 pmRNSPDMR / Director Dealings
2nd Jul 20187:00 amRNSPreliminary Results
20th Jun 20187:00 amRNSVirtTrade secures partnership with Formula 1
12th Jun 20187:00 amRNSBoard Appointment
21st May 20187:00 amRNSNotice of Preliminary Results
17th Apr 20187:00 amRNSBoard Change
26th Mar 20187:00 amRNSDeferred Consideration and Board Change
22nd Mar 20187:00 amRNSNew Direct Investment in Voxpopme
2nd Mar 20187:00 amRNSSale of Science Warehouse Limited
1st Feb 20187:00 amRNSMercia Annual Gala Dinner
22nd Dec 20177:00 amRNSBoard Appointment
18th Dec 20177:00 amRNSAmendment to Share Options
13th Dec 20177:00 amRNS£5.0million syndicated investment into Intechnica
11th Dec 20177:00 amRNS£3.8million syndicated investment into Medherant
6th Dec 20177:00 amRNSHalf Year Results
24th Nov 20177:00 amRNSImpression Technologies secures grant funding
17th Nov 20177:00 amRNSNew Direct Investment in £5.0m syndicated round
14th Nov 20177:00 amRNSLife Sciences & Biosciences sector update
1st Nov 20177:00 amRNSNew Partnership with the University of Edinburgh

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.